1. Home
  2. KLXE vs RNTX Comparison

KLXE vs RNTX Comparison

Compare KLXE & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KLX Energy Services Holdings Inc.

KLXE

KLX Energy Services Holdings Inc.

HOLD

Current Price

$2.50

Market Cap

45.6M

Sector

Energy

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.93

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLXE
RNTX
Founded
2018
2001
Country
United States
United States
Employees
N/A
10
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.6M
47.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
KLXE
RNTX
Price
$2.50
$1.93
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
236.7K
123.2K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$636,600,000.00
N/A
Revenue This Year
$3.89
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$1.02
52 Week High
$3.45
$2.22

Technical Indicators

Market Signals
Indicator
KLXE
RNTX
Relative Strength Index (RSI) 50.26 71.89
Support Level $2.14 $1.08
Resistance Level $3.10 $2.18
Average True Range (ATR) 0.24 0.20
MACD -0.00 0.04
Stochastic Oscillator 42.53 75.76

Price Performance

Historical Comparison
KLXE
RNTX

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: